We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Poniard Pharmaceuticals and AltheaDx Sign Agreement
News

Poniard Pharmaceuticals and AltheaDx Sign Agreement

Poniard Pharmaceuticals and AltheaDx Sign Agreement
News

Poniard Pharmaceuticals and AltheaDx Sign Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Poniard Pharmaceuticals and AltheaDx Sign Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Poniard Pharmaceuticals, Inc. has announced that it has selected AltheaDx, Inc.'s Express Pathway program to identify molecular signatures which may be correlated to platinum resistance.

Although platinum-based therapy is the standard of care for a broad range of solid tumors, its efficacy in most cancers is limited by the development of platinum resistance. Picoplatin, Poniard's lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction of clinical response to picoplatin treatment and may improve outcomes for patients with platinum-resistant cancers.

"We hope to better understand some of the biological mechanisms behind cancer's resurgence after platinum treatment, a significant treatment limiting problem for many patients with solid tumors," said Jerry McMahon, Chairman and CEO of Poniard Pharmaceuticals. "AltheaDx's high throughput gene expression platform facilitates the identification of molecular signature of platinum resistance that can guide therapeutic choices."

"Our mission at AltheaDx is to bring cancer diagnostics into clinical use," said David Macdonald, CEO of AltheaDx. "We are excited about Poniard's choice of our Express Pathway program to expedite identification, validation, and delivery of clinically valid molecular biomarkers to help guide more informed therapeutic decisions."

Advertisement